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Abstract 
Background: Only few studies, with small patient cohorts, have evaluated the effect of radiotherapy (RT) for 
metaplastic breast cancer (MBC). Hence, it is important to investigate the role of RT in MBC survival using a large 
population-database.
Methods: A retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) from 1973 to 
2015 was performed. We compared MBC patients with or without RT for overall survival (OS) and breast cancer-spe-
cific survival (BCSS) using univariate and multivariate Cox proportional hazard regressions before and after propensity 
score matching (PSM).
Results: From a total of 2267 patients diagnosed with MBC between 1998 and 2015, 1086 (47.9%) received RT. In the 
multivariate analysis before PSM, RT provided a better OS (HR 0.73; 95% CI 0.61–0.88; p = 0.001) and BCSS (HR 0.71; 
95% CI 0.58–0.88; p = 0.002). Multivariate analyses after PSM (n = 1066) confirmed that patients receiving RT (n = 506) 
survived longer than those without RT (OS, HR 0.64; 95% CI 0.51–0.80; p < 0.001 and BCSS, HR 0.64; 95% CI 0.50–0.83; 
p = 0.001). A longer OS was observed when RT was given to older patients (p = 0.001) and in case of large tumor size 
(p = 0.002). Intriguingly, patients with N0 stage showed better OS after RT (HR 0.69, P = 0.012).
Conclusions: Our findings support the beneficial effect of RT for MBC patients. In particular, older patients or with 
large tumor size have a greater survival benefit from RT. In conclusion, we have assessed the importance of the use of 
RT in MBC as survival factor and this could lead to the development of guidelines for this rare sub-type of tumors.
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Background
Metaplastic breast cancer (MBC) is a rare pathologic 
entity of the mammary gland accounting for about 0.2–
2% of breast cancer diagnoses and is generally associ-
ated with poor overall survival (OS) [1–3]. In 2010, MBC 
was defined as a unique histologic subtype by the World 
Health Organization [4]. The histologic classification of 
MBC is primarily based on the morphology of tumor cell 
types: purely epithelial or mesenchymal components, 
or a mixture of both [5]. Because of the increased cog-
nizance of MBC by pathologists, lately there has been 
a rise in diagnoses [6, 7]. In the past decade, four inde-
pendent databases confirmed the worse prognosis of 
MBC compared with non-MBC [7–10]. However, in 
light of its rarity, there are no association-endorsed treat-
ment guidelines specific to the management of MBC. 
In the recently revised National Comprehensive Cancer 
Network (NCCN) guidelines, metaplastic carcinoma, 
defined as more than 10% of the tumor phenotype, is an 
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used for its treatment are the same as for infiltrating 
ductal carcinoma (IDC) [11]. Compared with IDC, MBC 
tumors are often in a more advanced T stage, less likely 
to have nodal involvement, more likely to be hormone 
receptor negative, and of higher grade. A recent case–
control study demonstrated that the proportion of triple 
negative breast cancer (TNBC) in patients with stage I-III 
MBC is significantly higher than in IDC patients with 
the same stage (64.1% vs 12%, p < 0.001) [12]. Even when 
restricted to patients with TNBC, survival disparities 
persist between MBC and IDC [8].
Because of the high incidence of hormone receptor 
negativity in MBC, the majority of these patients receive 
systemic therapy after surgical treatment [13]. Endocrine 
therapy is unlikely to influence survival. On the other 
hand, Cimino et  al. [14] showed that adjuvant chemo-
therapy was associated with improved OS of patients 
with MBC, although the effect was limited to early-stage 
cases. Multiple other reports have demonstrated that 
MBC have a poorer response to chemotherapy regimens 
when compared to IDC [15–20]. Regarding the effective-
ness of radiotherapy (RT) for MBC, there is a limited 
number of studies and the investigated patient cohorts 
are generally small. Tseng and Martinez [10] studied a 
cohort of MBC patients treated between 1988 and 2006 
and concluded that the use of adjuvant RT indepen-
dently associates with improved OS. Similar results were 
reported in another study, indicating an improvement 
in local–regional recurrence (LRR) (p = 0.009) and OS 
(p < 0.001) after RT [21].
Thus, adjuvant RT should be explored as an approach 
to improve the dismal outcome of MBC. Indeed, precise 
guidelines are needed regarding the administration of 
adjuvant RT.
For these reasons, we analyzed a large database from 
the Surveillance, Epidemiology, and End Results (SEER) 
registry, through conventional methods and a propen-
sity score matching (PSM) approach to investigate the 
impact of postoperative RT and clinicopathologic factors 
of MBC on patient prognostics.
Methods
Study population and data sources
The database from the National Cancer Institute’s SEER 
program was queried to build our study cohort. The SEER 
database includes 18 registries covering approximately 
28% of the U.S. population and contains basic demo-
graphics and some clinical characteristics [22]. We used 
the SEER database, to include all participants diagnosed 
with microscopically confirmed MBC between the years 
1973–2015. Metaplastic histology was identified with 
SEER ICD-0-3 codes: 8052, 8070–8072, 8074, 8560, 8571, 
8572, 8575, and 8980. All patients diagnosed on autopsy 
or death certificate, or that presented stage IV MBC, with 
multiple primary lesions, or that received neoadjuvant 
RT were excluded from the study. The following clinico-
pathological factors were extracted from the SEER data-
base: age at diagnosis; marital status; race; TNM stage; 
tumor grade; hormone receptor status; T stage; N stage 
and treatment data including surgery for the primary site, 
chemotherapy record, and adjuvant radiotherapy.
Survival analysis and propensity matching
PSM is a tool for decreasing selection bias in non-rand-
omized studies and achieving balance covariates across 
treatment groups. The propensity score is the conditional 
probability of assignment to a particular treatment given 
a vector of observed covariates [23]. PSM permits the 
exclusion of bias factors that predict a type of treatment 
rather than the treatment per se. We created a matched 
dataset using PSM, using age (over and equal or under 
60 years old), marital status, race, T stage, N stage, tumor 
grade, estrogen receptor (ER) status, progesterone recep-
tor (PR) status, and treatment options including sur-
gery (lumpectomy or mastectomy) and chemotherapy 
(yes versus no) as covariates. Then, PSM was performed 
using 1:1 nearest neighbor matching to create a matched 
pair between the RT group and the No RT group. A Chi 
square test for categorical variables was used to compare 
across groups.
Statistical analysis
We employed univariate and multivariate Cox propor-
tional hazard models to identify factors associated with 
improved OS and breast cancer-specific survival (BCSS), 
using results reported as hazard ratio (HR) and 95% con-
fidence intervals (CI). OS was defined as the time from 
diagnosis to death or last follow-up. Patients with BCSS 
were identified using the cause of death provided by the 
death certificate. In order to account for missing values, 
multiple imputation methods using polytomous logistic 
regression were applied by MICE package in R software 
[24] and pooled the modeled data for a complete data 
set. The Kaplan–Meier method was used to estimate 
the survival curve and log-rank test was performed for 
comparison of survival between the nominal variables. 
All statistical analyses were conducted using R soft-
ware (ver.3.5.1) and SPSS statistical software (ver.24.0) 




Overall, 2267 patients who received treatment for 
MBC were identified from the SEER database. We 
divided the patients into two distinct groups, those 
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who received RT (case, n = 1086) and those who did not 
receive adjuvant RT (No RT-control, n = 1181) (Fig. 1). 
Because multiple clinical parameters were necessary 
for this study, only patients diagnosed with MBC dur-
ing 1998–2015 met the inclusion criteria (Additional 
file 1: Table S1). Clinical and pathologic characteristics 
of all MBC patients are presented in Additional file  2: 
Table  S2. The median follow-up for all MBC patients 
was 44  months. MBC tumors were more commonly 
of high grade (G3/G4: 72.4%), although 10.9% had 
unknown tumor grade, and no lymph node involve-
ment (76.8%), Patients were more commonly treated 
with mastectomy (58.3%). Breast-conserving surgery 
was carried out in 41.7% of patients. ER and PR were 
not expressed in 77.1% and 81.5% of MBC patients, 
respectively. Around 51.2% of patients underwent sen-
tinel lymph node biopsy (SLNB). Given the significant 
differences between case and control groups, a PSM 
was used to balance the distribution of most demo-
graphic and clinical characteristics. After matching, 
no variables were significantly different between cases 
and controls (Table 1). Participants were predominately 
matched within the common region (Additional file 3: 
Figure S1A).
Survival analyses in the whole SEER cohort
OS of the entire cohort was 70.7% at 5 years and 61.0% 
at 10 years while the BCSS of was 76.3% at 5 years and 
72.4% at 10  years. All the baseline characteristics and 
selected variables were included in univariate and mul-
tivariate analyses in relation to both OS and BCSS 
(Table  2). Patients who underwent mastectomy were 
found to receive less RT than patients undergoing breast 
conserving therapy (Additional file 3: Figure S1B), despite 
a much higher rate of tumors > 5  cm (Additional file  3: 
Figure S1C). As expected, increased age, higher N stage, 
and larger tumor size were associated with worse OS and 
BCSS, while receiving RT was strongly associated with 
better survival (OS: HR 0.73; 95% CI 0.61–0.88; p = 0.001 
BCSS: HR 0.71; 95% CI 0.58–0.88; p = 0.002). In fact, 
in patients receiving RT, OS was 77.1% at 5  years and 
66.9% at 10  years versus respectively 64.6% and 55.3% 
in patients not receiving RT (Fig. 2a). BCSS for patients 
receiving RT was 80.1% at 5 years and 74.5% at 10 years 
compared with 72.6% and 70.5% in patients not receiv-
ing RT (Fig.  2b). Chemotherapy was only associated 
with improved OS, but not BCSS in multivariate analysis 
(Table 2).
In order to assess the influence of RT regimen and 
chemotherapy regimen on our results, we determined the 
Fig. 1 Flow diagram of study cohort selection
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Table 1 Selected baseline characteristics for  the  SEER database study population divided per  study groups 
before and after PSM
SLNB Sentinel lymph node biopsy, ALND axillary lymph node dissection
Significant results are in italic
Characteristics Before PSM (2267) After PSM (1066)
No RT RT P-value No RT RT P-value
Age at diagnosis < 0.05 0.057
 < 60 504 (42.7%) 592 (54.5%) 264 (49.5%) 296 (55.5%)
 ≥ 60 677 (57.3%) 494 (45.5%) 269 (50.5%) 237 (44.5%)
Ethnicity < 0.05 0.667
 White 929 (78.7%) 825 (76.0%) 402 (75.4%) 408 (76.5%)
 Black 163 (13.8%) 190 (17.5%) 95 (17.8%) 85 (15.9%)
 Others 89 (7.5%) 71 (6.5%) 36 (6.8%) 40 (7.5%)
Marital status 0.263 0.736
 Single 185 (15.7%) 151 (13.9%) 86 (16.1%) 81 (15.2%)
 Married 996 (84.3%) 935 (86.1%) 447 (83.9%) 452 (84.8%)
Grade 0.539 0.472
 G1 64 (5.4%) 56 (5.2%) 23 (4.3%) 24 (4.5%)
 G2 173 (14.6%) 137 (12.6%) 66 (12.4%) 69 (12.9%)
 G3 888 (75.2%) 839 (77.3%) 416 (78.0%) 400 (75.0%)
 G4 56 (4.7%) 54 (5.0%) 28 (5.3%) 40 (7.5%)
ER status 0.413 0.456
 Negative 979 (82.9%) 885 (81.5%) 451 (84.6%) 441 (82.7%)
 Positive 202 (17.1%) 201 (18.5%) 82 (15.4%) 92 (17.3%)
PR status 0.058 0.192
 Negative 1044 (88.4%) 930 (85.6%) 475 (89.1%) 460 (86.3%)
 Positive 137 (11.6%) 156 (14.4%) 58 (10.9%) 73 (13.7%)
Stage T < 0.05 0.457
 ≤ 5 cm 937 (79.3%) 814 (75.0%) 373 (70.0%) 385 (72.2%)
 > 5 cm 244 (20.7%) 272 (25.0%) 160 (30.0%) 148 (27.8%)
Stage N 0.090 0.202
 N0 929 (78.7%) 811 (74.7%) 381 (71.5%) 382 (71.7%)
 N1 173 (14.6%) 195 (18.0%) 96 (18.0%) 112 (21.0%)
 N2 51 (4.3%) 45 (4.1%) 35 (6.6%) 22 (4.1%)
 N3 28 (2.4%) 35 (3.2%) 21 (3.9%) 17 (3.2%)
Stage TNM < 0.05 0.848
 I 247 (20.9%) 283 (26.1%) 109 (20.5%) 115 (21.6%)
 II 779 (66.0%) 605 (55.7%) 314 (58.9%) 314 (58.9%)
 III 155 (13.1%) 198 (18.2%) 110 (20.6%) 104 (19.5%)
Breast operation < 0.05 0.667
 Lumpectomy 254 (21.5%) 692 (63.7%) 248 (46.5%) 240 (45.0%)
 Mastectomy 927 (78.5%) 394 (36.3%) 285 (53.5%) 293 (55.0%)
Chemotherapy < 0.05 0.111
 Not done/unknown 548 (46.4%) 254 (23.4%) 176 (33.0%) 151 (28.3%)
 Done 633 (53.6%) 832 (76.6%) 357 (67.0%) 382 (71.7%)
Axilla LN operation 0.050 0.425
 SLNB 581 (49.2%) 580 (53.4%) 261 (49.0%) 247 (46.3%)
 ALND 600 (50.8%) 506 (46.6%) 272 (51.0%) 286 (53.7%)
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time points when significant changes in BC therapy took 
place and we split our initial cohort into two cohorts, 
before and after the changes in therapy. The most signifi-
cant changes in the RT regimen for breast cancer patients 
occurred during the period 1997–1999 [25–27]. In the 
present study, the majority (96.33%) of the MBC patients 
were diagnosed after 2000 (Additional file  1: Table  S1), 
implying that the radiotherapy received by these patients 
was mostly homogenous.
On the other hand, around 2005 we assisted to a signif-
icant change in breast cancer treatment which consisted 
in the addition of taxanes (docetaxel and paclitaxel) to 
the adjuvant chemotherapy regimens [28, 29]. There-
fore, we decided to divide the cohort in two time periods 
and repeat the analysis to test the effect of RT for MBC 
in the 2 different periods (Group 1: from 1998 to 2005 
and Group 2: from 2006 to 2015). Interestingly, for both 
groups we obtained a better OS and BCSS if radiother-
apy was performed (similar to the results on the whole 
cohort) (Additional file  4: Figure S2 A–D). Despite the 
changes in the chemotherapy regimen, the addition of 
radiotherapy to MBC is still beneficial. There was in fact 
a better OS for the 2006–2015 cohort (P < 0.0001; Addi-
tional file  4: Figure S2C) than the 1998–2005 cohort 
(P = 0.013, Additional file  4: Figure S2A) and the BCSS 
was minimally improved in the 2006–2015 cohort (1998–
2005 Cohort: P = 0.0024; 2006–2015 Cohort: P = 0.0019; 
Additional file 2: Table S2 B and D). This could be due in 
part because of the taxanes, which are known to increase 
the radio-sensitivity of cancer cells in vitro [30].
Table 2 Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study before PSM
SLNB Sentinel lymph node biopsy, ALND axillary lymph node dissection
Significant results are in italic
Characteristics Univariate Multivariate
OS BCSS OS BCSS
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis (< 60 as ref.)
 ≥ 60 1.92 (1.63–2.26) < 0.01 1.23 (1.02–1.48) < 0.05 1.81 (1.51–2.16) < 0.01 1.36 (1.11–1.66) < 0.001
Race (white as ref.)
 Black 1.02 (0.82–1.27) 0.843 1.12 (0.88–1.43) 0.364 1.01 (0.81–1.26) 0.958 0.97 (0.76–1.25) 0.828
 Others 0.91 (0.65–1.26) 0.583 0.98 (0.68–1.42) 0.922 0.95 (0.69–1.32) 0.763 0.97 (0.67–1.41) 0.872
Marital status (single as ref.)
 Married 0.92 (0.74–1.14) 0.449 0.78 (0.62–1.00) < 0.05 0.93 (0.74–1.17) 0.54 0.92 (0.71–1.18) 0.506
Grade (G1 as ref.)
 G2 1.23 (0.79–1.93) 0.36 1.08 (0.61–1.92) 0.786 1.08 (0.69–1.69) 0.747 0.93 (0.52–1.65) 0.801
 G3 1.5 (1.01–2.25) < 0.05 1.77 (1.07–2.92) < 0.05 1.18 (0.78–1.77) 0.438 1.14 (0.69–1.9) 0.605
 G4 1.94 (1.20–3.15) < 0.01 2.50 (1.40–4.49) < 0.01 1.56 (0.96–2.54) 0.076 1.65 (0.92–2.98) 0.095
ER status (negative as ref.)
 Positive 0.9 (0.73–1.12) 0.36 0.88 (0.68–1.13) 0.318 0.88 (0.68–1.14) 0.316 0.8 (0.59–1.08) 0.146
PR status (negative as ref.)
 Positive 0.8 (0.62–1.03) 0.077 0.87 (0.66–1.16) 0.339 0.81 (0.60–1.09) 0.162 0.95 (0.68–1.34) 0.779
Stage T (≤ 5 cm as ref.)
 > 5 cm 3.65 (3.11–4.28) < 0.01 4.55 (3.79–5.46) <  0.001 2.92 (2.44–3.49) < 0.01 3.44 (2.79–4.24) < 0.001
Stage N (N0 as ref.)
 N1 1.79 (1.48–2.17) < 0.01 2.35 (1.89–2.91) <  0.001 1.55 (1.26–1.91) < 0.01 1.78 (1.41–2.25) < 0.001
 N2 3.45 (2.60–4.59) < 0.01 4.01 (2.91–5.52) <  0.001 2.55 (1.88–3.46) < 0.01 2.49 (1.76–3.51) < 0.001
 N3 3.86 (2.78–5.36) < 0.01 5.03 (3.54–7.17) <  0.001 2.91 (2.06–4.11) < 0.01 3.33 (2.29–4.84) < 0.001
Breast operation (lumpectomy as ref.)
 Mastectomy 2.56 (2.14–3.06) < 0.01 2.75 (2.22–3.41) <  0.001 1.3 (1.05–1.61) < 0.05 1.32 (1.02–1.70) < 0.05
Chemotherapy (not done/unknown as ref.)
 Done 0.62 (0.53–0.72) < 0.01 0.99 (0.82–1.2) 0.934 0.71 (0.60–0.85) < 0.001 1.02 (0.82–1.27) 0.848
Radiotherapy (not done as ref.)
 Done 0.62 (0.53–0.73) < 0.001 0.73 (0.61–0.88) < 0.001 0.73 (0.61–0.88) 0.001 0.71 (0.58–0.88) < 0.01
Axilla LN operation (SLNB as ref.)
 ALND 1.91 (1.62–2.25) < 0.001 2.18 (1.79–2.65) < 0.001 1.17 (0.97–1.42) 0.096 1.14 (0.91–1.43) 0.254
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Survival analysis in propensity score-matched cohort
In the matched cohort, univariate analysis revealed simi-
lar prognostic factors for OS and BCSS to the results of 
unmatched cohort: age, PR status, marital status, larger 
tumor size, higher N stage and, axillary lymph node 
dissection (ALND). Only age did not result a prognos-
tic factor for BCSS. Survival curves according to the 
RT are shown in Fig.  2c, d. Multivariate analysis also 
showed that patients receiving RT survived significantly 
longer than those without RT (5-year OS, 74.2% vs 61.5% 
p < 0.001; BCSS, 71.4% vs 64.9% p < 0.001). Additionally, 
age, marital status, larger tumor size, and higher N stage 
were maintained as prognostic factors for OS and BCSS. 
Results of survival analysis in the propensity-matched 
cohort are summarized in Table 3.
Exploratory subgroup analysis assessing the benefit of RT 
according to the clinical characteristics
To detect precise subgroups of patients that could ben-
efit from RT, PSM was performed for each subgroup 
including age, tumor size, N stage, breast operation, 
and ALND as covariates. A significantly increased OS 
was observed when RT was given to older patients 
(≥ 60  years old) (HR 0.614, P = 0.001) and those with 
larger tumor size (HR 0.593, P = 0.01) (Fig.  3a, b). In 
the subgroup of N0 stage, RT was also associated with 
an improvement of OS (Fig. 3c). After PSM, RT main-
tained the significant survival advantage in the N0 
stage subgroup (Fig.  3d). MBC patients who received 
RT also had better survival in N1 stage subgroup 
(Fig.  3e). RT could reduce the risk of death by 58.0% 
for patients with N1 stage, while for patients with N0 
stage the reduction was only 30.6%. Patients receiving 
breast-conserving surgery and RT demonstrated 43.7% 
decrease in death from any cause when compared with 
patients receiving mastectomy and RT, these last show-
ing a reduction of only 25.7%. Patients who underwent 
SLNB and ALND had similar benefit from RT (42.9% vs 
31.9.0% reduction of deaths, respectively) (Additional 
file 5: Figure S3).
Discussion
To our knowledge, this is the first population-based study 
using PSM analysis to assess the role of RT in treating 
MBC. In this study, significant improvements in survival 
Fig. 2 OS and BCSS of MBC patients displayed as Kaplan–Meier curve stratified according to RT. a OS curves of RT cohort versus no RT cohort 
before PSM. b BCSS curves of RT cohort versus No RT cohort before PSM. c OS curves of RT cohort versus no RT cohort after PSM. d BCSS curves of 
RT cohort versus No RT cohort after PSM
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were observed for patients treated with RT, especially 
when elderly (≥ 60 years), and with large tumor size. The 
beneficial effect on survival observed in the SEER data-
base highlights the importance of RT in the management 
of MBC.
As a rare breast cancer subtype, the optimal treat-
ment options for MBC are relatively unknown. The role 
of RT in improving survival for locally advanced IDC 
and post breast-conserving operations has been estab-
lished well [8, 31]. However, for MBC the effective-
ness of RT is yet to be defined. Although MBC is more 
aggressive than IDC, overall the use of RT is lower in 
the MBC population compared to IDC (48.3% MBC vs 
54.3% IDC, P = 0.0001) [8]: in fact, only 62% of MBC 
patients who undergo lumpectomy received RT, while 
post-lumpectomy RT is a standard therapy for treating 
IDC patients [10]. In our study, 47.9% of MBC received 
RT, and the treatment was given to 73.2% of patients who 
received a breast-conserving operation. Rakha et al. [32] 
reported no association between RT and survival out-
comes in patients with MBC, but several other studies 
demonstrated that the use of adjuvant RT independently 
associates with improved survival [8]. In a study on 1501 
MBC patients, RT was found to be associated with better 
overall and disease-free survivals [10]. Another cohort 
study showed that RT was independently associated 
with better survival of MBC patients (HR 0.81, 95% CI 
0.78–0.84). Similar results were reported in a case series 
Table 3 Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study after PSM
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection
Significant results are in italic
Characteristics Univariate Multivariate
OS BCSS OS BCSS
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis (< 60 as ref.)
 ≥ 60 1.49 (1.20–1.85) < 0.001 1 (0.78–1.289) 0.987 1.6 (1.26–2.05) < 0.001 1.23 (0.94–1.62) 0.138
Race (white as ref.)
 Black 1.18 (0.89–1.60) 0.243 1.22 (0.89–1.68) 0.22 1.03 (0.77–1.39) 0.842 0.95 (0.68–1.32) 0.755
 Others 0.96 (0.61–1.49) 0.842 1.07 (0.66–1.73) 0.798 1.09 (0.69–1.71) 0.723 1.06 (0.65–1.74) 0.813
Marital status (single as ref.)
 Married 0.7 (0.53–0.94) < 0.05 0.62 (0.46–0.84) < 0.01 0.68 (0.50–0.91) 0.01 0.68 (0.49–0.95) < 0.05
Grade (G1 as ref.)
 G2 0.98 (0.48–2.01) 0.958 0.8 (0.33–1.93) 0.617 0.96 (0.47–1.98) 0.918 0.8 (0.33–1.94) 0.62
 G3 1.58 (0.84–2.97) 0.155 1.8 (0.85–3.82) 0.127 1.23 (0.65–2.32) 0.529 1.26 (0.59–2.68) 0.557
 G4 1.34 (0.64–2.80) 0.439 1.58 (0.67–3.77) 0.299 1.34 (0.64–2.81) 0.443 1.44 (0.60–3.44) 0.411
ER status (negative as ref.)
 Positive 0.82 (0.60–1.14) 0.239 0.84 (0.59–1.21) 0.353 0.83 (0.57–1.21) 0.331 0.76 (0.50–1.15) 0.19
PR status (negative as ref.)
 Positive 0.63 (0.43–0.93) < 0.05 0.77 (0.51–1.15) 0.204 0.67 (0.43–1.04) 0.074 0.89 (0.56–1.42) 0.627
Stage T (≤ 5 cm as ref.)
 > 5 cm 3.84 (3.08–4.78) < 0.001 4.41 (3.44–5.66) < 0.001 2.99 (2.31–3.86) < 0.001 3.18 (2.39–4.24) < 0.001
Stage N (N0 as ref.)
 N1 1.56 (1.20–2.05) 0.001 2.02 (1.51–2.71) < 0.001 1.21 (0.91–1.61) 0.191 1.43 (1.04–1.95) < 0.05
 N2 2.91 (2.02–4.20) < 0.001 3.29 (2.19–4.95) < 0.001 1.84 (1.24–2.72) < 0.01 1.82 (1.17–2.82) < 0.01
 N3 3.27 (2.14–5.00) < 0.001 4.04 (2.55–6.40) < 0.001 2.2 (1.39–3.48) 0.001 2.41 (1.46–3.98) 0.001
Breast operation (lumpectomy as ref.)
 Mastectomy 2.6 (2.04–3.31) < 0.001 3.18 (2.38–4.25) < 0.001 1.46 (1.08–1.98) < 0.05 1.52 (1.06–2.18) < 0.05
Chemotherapy (not done/unknown as ref.)
 Done 0.84 (0.67–1.05) 0.12 1.35 (1.02–1.80) < 0.05 0.75 (0.58–1.00) < 0.05 1.08 (0.79–1.48) 0.617
Radiotherapy (not done as ref.)
 Done 0.62 (0.50–0.77) < 0.001 0.65 (0.51–0.84) < 0.001 0.64 (0.51–0.80) < 0.001 0.64 (0.50–0.83) 0.001
Axilla LN operation (SLNB as ref.)
 ALND 1.89 (1.49–2.39) < 0.001 2.22 (1.68–2.92) < 0.001 1.17 (0.89–1.54) 0.254 1.16 (0.85–1.60) 0.347
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study that indicated an improvement in the OS of MBC 
patients after RT [3]. In our study, univariate and multi-
variate results demonstrated that RT was independently 
associated with an improvement in OS and BCSS and the 
results were independent of the changes that occurred in 
chemotherapy regimen over the years. PSM analyses also 
confirmed these results.
Currently, RT practices on MBC are comparable with 
those on IDC [33]. Nevertheless, there are significant 
biological differences between MBC and IDC. Com-
pared to IDC, MBC cells express lower levels of ER, 
PR, and HER-2 (a phenotype similar to TNBC) and 
express higher levels of Ki-67 and p53 [3, 6]. Molecular 
subtyping reveals that MBC tumors frequently display 
basal-like phenotypes. However, patients with triple-
negative MBC have worse survival than patients with 
triple-negative IDC [15]. Moreover, patients with MBC 
have larger, higher-grade tumors with less involvement 
of the regional lymph nodes than IDC subjects [33, 34]. 
Additionally, MBC tends to disseminate hematogenously 
rather than lymphatic [13].
Fig. 3 OS of MBC patients displayed as Kaplan–Meier curves according to RT for different patient subgroups: a age ≥ 60 years and age < 60 years 
subgroup with or without RT after PSM. b Tumor size ≤ 5 cm and a > 5 cm subgroup with or without RT after PSM. c N0 subgroup with or without 
RT before PSM. d N0 subgroup with or without RT after PSM. e N1 subgroup with or without RT after PSM
Page 9 of 12Li et al. J Transl Med          (2019) 17:318 
Wargot et al. [35] showed that MBC has an incidence 
of axillary lymph node metastasis ranging from 6 to 26%, 
depending on the subtype of MBC. Our study reported 
that only 23.2% of MBC had lymph node involvement. 
Since in MBC there is a high potential for metastatic 
spread to the lung and brain via blood vessels [36, 37], 
circulating tumor cells (CTC) may be playing a role in the 
metastatic progression. Some findings showed that the 
presence of CTC is an independent predictor of relapse 
and death in patients with operable breast cancer [38] 
and this could also be the case of MBC. In addition, sev-
eral mutated genes were identified to correlate with the 
prognosis of patients with MBC. The principal immuno-
histochemical feature of MBC cells is the positive CD44 
and the overexpression of the Yes-associated protein, 
both of which are stem cells markers [13, 39]. Genomic 
profiling has shown a down-regulation of the DNA repair 
pathways including BRCA1, PTEN and TOP2A [40, 41]. 
In some studies, up to 35% of MBC patients had PIK3CA 
mutations [42] and a PIK3CA inhibitor has also shown 
efficacy in improving outcomes of metastatic MBC [43]. 
A recent study showed that 46% of MBC expressed 
PD-L1 [44], opening up the possibility of trials using 
immune checkpoint inhibitors for MBC, as is now being 
tested in TNBC trials [45]. Finally, the presence of mes-
enchymal and sarcomatous elements also may explain 
the different biologic behavior and pattern of metastasis. 
Therefore, precise guidelines are needed regarding the 
administration of adjuvant RT.
Current guidelines recommend adjuvant RT for breast 
cancer patients with 4 or more metastatic axillary nodes, 
large primary tumor (> 5  cm) or after lumpectomy [46, 
47]. MBC is characterized by large tumor size and rapid 
growth, hence RT should be considered. In the National 
Cancer Data Base (NCDB) study, a higher AJCC stage 
was common for MBC patients, despite having more 
lymph node-negative tumors. Hence, the tumor stage is 
strongly influenced by the tumor size. Compared with 
IDC patients, who at diagnosis have usually T1 tumors 
(65.2%), only 29.5% of MBC patients are in T1 stage 
at presentation [7]. A cohort study showed that RT is 
not useful for patients undergoing mastectomy with 
tumors < 5 cm or with < 4 metastatic axillary lymph nodes 
[10]. We confirmed these findings in our PSM analyses, 
after stratifying patients according to tumor size: RT 
was associated with improved OS in MBC patients with 
larger tumor size (> 5  cm). When stratified by N stage, 
we found that patients with both N0 and N1 could ben-
efit from RT. Low likelihood of lymphatic involvement in 
MBC may be the cause of this result. However, RT could 
reduce the risk of death by 50.3% for patients with N2 
stage, whereas for patients with N1 stage the reduction is 
only 26.2%. Due to the small sample sizes obtained after 
propensity matching, we did not find any survival benefit 
for stage N3 and N4.
Age over/equal 60  years at diagnosis was found to be 
a poor survival factor in multivariate analysis. Similar 
results have been reported in other population-based 
studies including SEER database (HR 2.9 95% CI 2.1–3.9) 
[9] and NCDB database (HR 1.018 95% CI 1.009–1.027) 
[48]. One of the reasons is that older women patients 
may not always get the most optimal treatment. Assum-
ing older women may not handle treatment side effects as 
well as younger women, doctors tend to treat breast can-
cer in older women less aggressively. Therefore, the use of 
RT decreases with increasing age at diagnosis [49]. In our 
study, elderly (≥ 60  years old) received more rarely RT 
(54.5% vs 45.5%) compared to younger patients. Truong 
et  al. [50] reported that radiation omission was signifi-
cantly associated with increased relapse rates and poorer 
OS and BCSS. The highly aggressive MBC probably is 
one of the reasons for this negative outcome. Our sub-
group analyses revealed that RT significantly improved 
OS in older MBC patients. Furthermore, the use of RT 
was shown to be associated with improved survival in 
patients, regardless of the surgical procedure performed. 
Interestingly, patients receiving breast-conserving sur-
gery, and RT demonstrated a 43.7% decrease in death 
from any cause compared with patients receiving mas-
tectomy and RT which showed a reduction of only 25.7%. 
Patients who underwent SLNB and ALND benefited sim-
ilarly from RT (42.9% vs 31.9%).
Besides the large population included and the inter-
esting results obtained for RT, we acknowledge some 
limitations to our study. One important limitation is 
the absence of information on systemic chemotherapy 
and endocrine therapy regimens due to the design of 
the SEER database. Missing these important parameters 
could lead to potential bias. Despite the large popula-
tion, 2267 patients, selected for this study, the sample size 
was not big enough for more detailed subgroup analyses, 
such as age, ethnicity, and stage before PSM. The use of 
the PSM method might reduce the bias caused by the 
imbalanced distribution of the obtained covariates. In 
addition, the SEER database does not provide any data 
on some risk factors for breast cancer, such as smoking 
and menstrual status, which may contribute to additional 
study bias. Regarding RT in the SEER database, there 
is no information on the dose or intended target. Thus, 
we had no data about the radiation dose time, methods, 
intent, side effects, etc. which may all contribute to the 
survival. Interestingly, the large time interval of diagnosis 
for MBC patients may have been a bias considering that 
during this period, changes in chemotherapy regimen 
have been documented. For this reason, we divided the 
cohort in two time periods (1998–2005 and 2006–2015), 
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before and after the addition of taxanes [28, 29]. We 
repeated the analysis to test the effect of RT for MBC in 
these 2 different sub-cohorts, giving a weight to the intro-
duction of the use of taxanes in 2005. Interestingly, for 
both groups we obtained a better OS and BCSS if RT was 
performed, independently of the period of diagnosis [12]. 
Nevertheless, the SEER database usually has high com-
pleteness and is representative of the real patient popula-
tion [22]. The results obtained are therefore robust from 
the statistical point of view and even after both multivari-
ate and PSM analyses were performed, the OS and BCSS 
did not change appreciably.
Conclusions
Based on our results, the MBC patients receiving RT 
resulted having a better BCSS and OS compared to MBC 
patients not treated with RT, in particular in presence 
of large tumors and elderly patients (≥ 60  years). Addi-
tionally, RT was associated with improved outcomes 
in patients with N0 stage, hence MBC patients with N0 
stage could also benefit from RT. Further prospective 
studies with a sufficient sample size are needed to con-
firm these findings. In addition, although axillary node 
dissection is likely to add very little in terms of improved 
outcomes in MBC [48], omitting axillary node dissection 
could be evaluated in future studies to define the guide-
lines for MBC.
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